Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and MS-PCR, respectively. Results: Mutations...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pandith, Arshad A., Qasim, Iqbal, Baba, Shahid M., Koul, Aabid, Zahoor, Wani, Afroze, Dil, Lateef, Adil, Manzoor, Usma, Bhat, Ina A., Sanadhya, Dheera, R. Bhat, Abdul, Ramzan, Altaf U.
Format: Dataset
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Pandith, Arshad A.
Qasim, Iqbal
Baba, Shahid M.
Koul, Aabid
Zahoor, Wani
Afroze, Dil
Lateef, Adil
Manzoor, Usma
Bhat, Ina A.
Sanadhya, Dheera
R. Bhat, Abdul
Ramzan, Altaf U.
description The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and MS-PCR, respectively. Results: Mutations found in IDH1/2 genes totalled 63.4% (N=40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). IDH1mutants presented more, 60.5% in MGMT promoter methylated cases (p=0.03). IDH1 mutant cases had better survival for GBM and oligodendrioglioma (log rank p=0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (HR: 0.59, p=0.031). Combination of both biomarkers showed better prognosis on temozolomide (p
doi_str_mv 10.25402/fsg.13372904
format Dataset
fullrecord <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_25402_fsg_13372904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_25402_fsg_13372904</sourcerecordid><originalsourceid>FETCH-datacite_primary_10_25402_fsg_133729043</originalsourceid><addsrcrecordid>eNqVjrkOgkAURaexMGpp_35AWY2xdsOCzn7yhAdMMgsZHhoL_12C-gE29xZ3yRFiGYXreJOGcVB19TpKkm28C9OpeJ3w7jzeNIF3g7gKLocsCmIwPSMrZztAVVIJD8UN5Of8Cq13xjF5qMkSGOLmqccqKAvcDCc9F86MZ-0QkOXuMzeoVW3RMtRaOYNzMalQd7T4-kysTsfrPluVyFgoJtl6ZdA_ZRTKEV8O-PKHn_zbfwNdElPj</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>dataset</recordtype></control><display><type>dataset</type><title>Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><source>DataCite</source><creator>Pandith, Arshad A. ; Qasim, Iqbal ; Baba, Shahid M. ; Koul, Aabid ; Zahoor, Wani ; Afroze, Dil ; Lateef, Adil ; Manzoor, Usma ; Bhat, Ina A. ; Sanadhya, Dheera ; R. Bhat, Abdul ; Ramzan, Altaf U.</creator><creatorcontrib>Pandith, Arshad A. ; Qasim, Iqbal ; Baba, Shahid M. ; Koul, Aabid ; Zahoor, Wani ; Afroze, Dil ; Lateef, Adil ; Manzoor, Usma ; Bhat, Ina A. ; Sanadhya, Dheera ; R. Bhat, Abdul ; Ramzan, Altaf U.</creatorcontrib><description>The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and MS-PCR, respectively. Results: Mutations found in IDH1/2 genes totalled 63.4% (N=40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). IDH1mutants presented more, 60.5% in MGMT promoter methylated cases (p=0.03). IDH1 mutant cases had better survival for GBM and oligodendrioglioma (log rank p=0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (HR: 0.59, p=0.031). Combination of both biomarkers showed better prognosis on temozolomide (p&lt;0.05). Conclusions: IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival.</description><identifier>DOI: 10.25402/fsg.13372904</identifier><language>eng</language><publisher>Taylor &amp; Francis</publisher><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,1888</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.25402/fsg.13372904$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Pandith, Arshad A.</creatorcontrib><creatorcontrib>Qasim, Iqbal</creatorcontrib><creatorcontrib>Baba, Shahid M.</creatorcontrib><creatorcontrib>Koul, Aabid</creatorcontrib><creatorcontrib>Zahoor, Wani</creatorcontrib><creatorcontrib>Afroze, Dil</creatorcontrib><creatorcontrib>Lateef, Adil</creatorcontrib><creatorcontrib>Manzoor, Usma</creatorcontrib><creatorcontrib>Bhat, Ina A.</creatorcontrib><creatorcontrib>Sanadhya, Dheera</creatorcontrib><creatorcontrib>R. Bhat, Abdul</creatorcontrib><creatorcontrib>Ramzan, Altaf U.</creatorcontrib><title>Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><description>The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and MS-PCR, respectively. Results: Mutations found in IDH1/2 genes totalled 63.4% (N=40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). IDH1mutants presented more, 60.5% in MGMT promoter methylated cases (p=0.03). IDH1 mutant cases had better survival for GBM and oligodendrioglioma (log rank p=0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (HR: 0.59, p=0.031). Combination of both biomarkers showed better prognosis on temozolomide (p&lt;0.05). Conclusions: IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival.</description><fulltext>true</fulltext><rsrctype>dataset</rsrctype><creationdate>2020</creationdate><recordtype>dataset</recordtype><sourceid>PQ8</sourceid><recordid>eNqVjrkOgkAURaexMGpp_35AWY2xdsOCzn7yhAdMMgsZHhoL_12C-gE29xZ3yRFiGYXreJOGcVB19TpKkm28C9OpeJ3w7jzeNIF3g7gKLocsCmIwPSMrZztAVVIJD8UN5Of8Cq13xjF5qMkSGOLmqccqKAvcDCc9F86MZ-0QkOXuMzeoVW3RMtRaOYNzMalQd7T4-kysTsfrPluVyFgoJtl6ZdA_ZRTKEV8O-PKHn_zbfwNdElPj</recordid><startdate>20201214</startdate><enddate>20201214</enddate><creator>Pandith, Arshad A.</creator><creator>Qasim, Iqbal</creator><creator>Baba, Shahid M.</creator><creator>Koul, Aabid</creator><creator>Zahoor, Wani</creator><creator>Afroze, Dil</creator><creator>Lateef, Adil</creator><creator>Manzoor, Usma</creator><creator>Bhat, Ina A.</creator><creator>Sanadhya, Dheera</creator><creator>R. Bhat, Abdul</creator><creator>Ramzan, Altaf U.</creator><general>Taylor &amp; Francis</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20201214</creationdate><title>Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><author>Pandith, Arshad A. ; Qasim, Iqbal ; Baba, Shahid M. ; Koul, Aabid ; Zahoor, Wani ; Afroze, Dil ; Lateef, Adil ; Manzoor, Usma ; Bhat, Ina A. ; Sanadhya, Dheera ; R. Bhat, Abdul ; Ramzan, Altaf U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-datacite_primary_10_25402_fsg_133729043</frbrgroupid><rsrctype>datasets</rsrctype><prefilter>datasets</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Pandith, Arshad A.</creatorcontrib><creatorcontrib>Qasim, Iqbal</creatorcontrib><creatorcontrib>Baba, Shahid M.</creatorcontrib><creatorcontrib>Koul, Aabid</creatorcontrib><creatorcontrib>Zahoor, Wani</creatorcontrib><creatorcontrib>Afroze, Dil</creatorcontrib><creatorcontrib>Lateef, Adil</creatorcontrib><creatorcontrib>Manzoor, Usma</creatorcontrib><creatorcontrib>Bhat, Ina A.</creatorcontrib><creatorcontrib>Sanadhya, Dheera</creatorcontrib><creatorcontrib>R. Bhat, Abdul</creatorcontrib><creatorcontrib>Ramzan, Altaf U.</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Pandith, Arshad A.</au><au>Qasim, Iqbal</au><au>Baba, Shahid M.</au><au>Koul, Aabid</au><au>Zahoor, Wani</au><au>Afroze, Dil</au><au>Lateef, Adil</au><au>Manzoor, Usma</au><au>Bhat, Ina A.</au><au>Sanadhya, Dheera</au><au>R. Bhat, Abdul</au><au>Ramzan, Altaf U.</au><format>book</format><genre>unknown</genre><ristype>DATA</ristype><title>Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><date>2020-12-14</date><risdate>2020</risdate><abstract>The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and MS-PCR, respectively. Results: Mutations found in IDH1/2 genes totalled 63.4% (N=40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). IDH1mutants presented more, 60.5% in MGMT promoter methylated cases (p=0.03). IDH1 mutant cases had better survival for GBM and oligodendrioglioma (log rank p=0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (HR: 0.59, p=0.031). Combination of both biomarkers showed better prognosis on temozolomide (p&lt;0.05). Conclusions: IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival.</abstract><pub>Taylor &amp; Francis</pub><doi>10.25402/fsg.13372904</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier DOI: 10.25402/fsg.13372904
ispartof
issn
language eng
recordid cdi_datacite_primary_10_25402_fsg_13372904
source DataCite
title Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T03%3A49%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Pandith,%20Arshad%20A.&rft.date=2020-12-14&rft_id=info:doi/10.25402/fsg.13372904&rft_dat=%3Cdatacite_PQ8%3E10_25402_fsg_13372904%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true